Champions Oncology, Inc. (CSBR)
USD 7.08
(-5.47%)
USD 7.08
(-5.47%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -7.35 Million USD | -65.34% |
| 2023 | -4.44 Million USD | -832.95% |
| 2022 | 607 Thousand USD | 79.59% |
| 2021 | 338 Thousand USD | 123.02% |
| 2020 | -1.46 Million USD | -643.7% |
| 2019 | 270 Thousand USD | 119.94% |
| 2018 | -1.35 Million USD | 80.11% |
| 2017 | -6.8 Million USD | 34.0% |
| 2016 | -10.31 Million USD | 22.07% |
| 2015 | -13.23 Million USD | -111.47% |
| 2014 | -6.26 Million USD | 1.37% |
| 2013 | -6.34 Million USD | 29.98% |
| 2012 | -9.06 Million USD | -73.16% |
| 2011 | -5.23 Million USD | -78.79% |
| 2010 | -2.92 Million USD | -25.67% |
| 2009 | -2.33 Million USD | -35478.07% |
| 2008 | 6586.00 USD | 103.87% |
| 2007 | -170.05 Thousand USD | -18.0% |
| 2006 | -144.11 Thousand USD | 41.55% |
| 2005 | -246.54 Thousand USD | -128.94% |
| 2004 | -107.68 Thousand USD | 26.24% |
| 2003 | -145.99 Thousand USD | 0.89% |
| 2002 | -147.31 Thousand USD | 68.59% |
| 2001 | -468.93 Thousand USD | -3221.63% |
| 2000 | 15.02 Thousand USD | -24.89% |
| 1999 | 20 Thousand USD | -71.43% |
| 1998 | 70 Thousand USD | 0.0% |
| 1997 | 70 Thousand USD | 40.0% |
| 1996 | 50 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | -2.57 Million USD | -31.82% |
| 2024 Q4 | 164 Thousand USD | 106.36% |
| 2024 FY | -6.92 Million USD | -55.56% |
| 2024 Q1 | -2.55 Million USD | -48.89% |
| 2024 Q2 | -1.95 Million USD | 23.39% |
| 2023 Q1 | -284 Thousand USD | 8.68% |
| 2023 Q4 | -1.71 Million USD | 30.27% |
| 2023 Q3 | -2.45 Million USD | -35214.29% |
| 2023 Q2 | 7000.00 USD | 102.46% |
| 2023 FY | -4.44 Million USD | -832.95% |
| 2022 Q3 | 830 Thousand USD | 215.59% |
| 2022 Q4 | -311 Thousand USD | -137.47% |
| 2022 FY | 607 Thousand USD | 79.59% |
| 2022 Q1 | -175 Thousand USD | 61.62% |
| 2022 Q2 | 263 Thousand USD | 250.29% |
| 2021 FY | 338 Thousand USD | 123.02% |
| 2021 Q1 | 24 Thousand USD | 101.26% |
| 2021 Q2 | 7000.00 USD | -70.83% |
| 2021 Q3 | 763 Thousand USD | 10800.0% |
| 2021 Q4 | -456 Thousand USD | -159.76% |
| 2020 Q4 | -1.91 Million USD | -541.11% |
| 2020 Q2 | 291 Thousand USD | 147.39% |
| 2020 Q3 | 433 Thousand USD | 48.8% |
| 2020 Q1 | -614 Thousand USD | -424.79% |
| 2020 FY | -1.46 Million USD | -643.7% |
| 2019 Q1 | 481 Thousand USD | 180.98% |
| 2019 Q4 | -117 Thousand USD | 68.38% |
| 2019 FY | 270 Thousand USD | 119.94% |
| 2019 Q3 | -370 Thousand USD | -234.55% |
| 2019 Q2 | 275 Thousand USD | -42.83% |
| 2018 Q2 | -70 Thousand USD | 88.69% |
| 2018 Q3 | -67 Thousand USD | 4.29% |
| 2018 Q4 | -594 Thousand USD | -786.57% |
| 2018 Q1 | -619 Thousand USD | 74.09% |
| 2018 FY | -1.35 Million USD | 80.11% |
| 2017 Q4 | -2.38 Million USD | -70.52% |
| 2017 Q2 | -493 Thousand USD | 80.46% |
| 2017 Q1 | -2.52 Million USD | 1.02% |
| 2017 FY | -6.8 Million USD | 34.0% |
| 2017 Q3 | -1.4 Million USD | -184.18% |
| 2016 Q1 | -2.89 Million USD | -20.51% |
| 2016 FY | -10.31 Million USD | 22.07% |
| 2016 Q4 | -2.54 Million USD | -7.42% |
| 2016 Q3 | -2.37 Million USD | 4.81% |
| 2016 Q2 | -2.49 Million USD | 13.95% |
| 2015 Q1 | -3.72 Million USD | -57.47% |
| 2015 FY | -13.23 Million USD | -111.47% |
| 2015 Q2 | -3.66 Million USD | 1.69% |
| 2015 Q3 | -3.41 Million USD | 6.74% |
| 2015 Q4 | -2.4 Million USD | 29.69% |
| 2014 Q3 | -1.33 Million USD | 21.34% |
| 2014 Q1 | -766 Thousand USD | 63.73% |
| 2014 FY | -6.26 Million USD | 1.37% |
| 2014 Q4 | -2.36 Million USD | -76.98% |
| 2014 Q2 | -1.7 Million USD | -122.06% |
| 2013 FY | -6.34 Million USD | 29.98% |
| 2013 Q4 | -2.11 Million USD | -193.33% |
| 2013 Q3 | -720 Thousand USD | 62.42% |
| 2013 Q2 | -1.91 Million USD | -19.82% |
| 2013 Q1 | -1.59 Million USD | 38.55% |
| 2012 FY | -9.06 Million USD | -73.16% |
| 2012 Q4 | -2.6 Million USD | -46.76% |
| 2012 Q1 | -2.21 Million USD | 21.79% |
| 2012 Q2 | -2.46 Million USD | -11.52% |
| 2012 Q3 | -1.77 Million USD | 28.19% |
| 2011 FY | -5.23 Million USD | -78.79% |
| 2011 Q1 | -603 Thousand USD | -9.24% |
| 2011 Q2 | -1.01 Million USD | -68.33% |
| 2011 Q3 | -786 Thousand USD | 22.56% |
| 2011 Q4 | -2.83 Million USD | -260.18% |
| 2010 Q1 | -1 Million USD | 18.76% |
| 2010 Q3 | -784 Thousand USD | -34.25% |
| 2010 FY | -2.92 Million USD | -25.67% |
| 2010 Q4 | -552 Thousand USD | 29.59% |
| 2010 Q2 | -584 Thousand USD | 42.06% |
| 2009 Q2 | -256.7 Thousand USD | -36.4% |
| 2009 Q1 | -188.19 Thousand USD | 58.3% |
| 2009 FY | -2.33 Million USD | -35478.07% |
| 2009 Q4 | -1.24 Million USD | -92.59% |
| 2009 Q3 | -644.28 Thousand USD | -150.98% |
| 2008 Q3 | 604.94 Thousand USD | 502.76% |
| 2008 Q1 | 3209.00 USD | 103.34% |
| 2008 FY | 6586.00 USD | 103.87% |
| 2008 Q2 | -150.19 Thousand USD | -4780.52% |
| 2008 Q4 | -451.36 Thousand USD | -174.61% |
| 2007 Q4 | -95.97 Thousand USD | -158.0% |
| 2007 Q3 | -37.19 Thousand USD | -90.1% |
| 2007 Q2 | -19.56 Thousand USD | -12.98% |
| 2007 Q1 | -17.32 Thousand USD | -744.83% |
| 2007 FY | -170.05 Thousand USD | -18.0% |
| 2006 Q4 | 2686.00 USD | 110.85% |
| 2006 Q2 | -43.84 Thousand USD | 37.36% |
| 2006 Q3 | -24.75 Thousand USD | 43.54% |
| 2006 Q1 | -69.99 Thousand USD | -1721.47% |
| 2006 FY | -144.11 Thousand USD | 41.55% |
| 2005 Q3 | -77.75 Thousand USD | -168.53% |
| 2005 Q2 | -28.95 Thousand USD | 0.0% |
| 2005 Q1 | -28.95 Thousand USD | -447.74% |
| 2005 FY | -246.54 Thousand USD | -128.94% |
| 2005 Q4 | 4317.00 USD | 105.55% |
| 2004 Q1 | -47.34 Thousand USD | 26.34% |
| 2004 Q4 | 8327.00 USD | 123.06% |
| 2004 Q3 | -36.1 Thousand USD | -10.91% |
| 2004 Q2 | -32.55 Thousand USD | 31.24% |
| 2004 FY | -107.68 Thousand USD | 26.24% |
| 2003 FY | -145.99 Thousand USD | 0.89% |
| 2003 Q1 | -75.48 Thousand USD | 4.84% |
| 2003 Q2 | 36.89 Thousand USD | 148.88% |
| 2003 Q4 | -64.27 Thousand USD | -49.04% |
| 2003 Q3 | -43.12 Thousand USD | -216.9% |
| 2002 Q4 | -79.31 Thousand USD | -113.92% |
| 2002 FY | -147.31 Thousand USD | 68.59% |
| 2002 Q3 | -37.07 Thousand USD | -1353.06% |
| 2002 Q1 | -33.87 Thousand USD | 53.45% |
| 2002 Q2 | 2959.00 USD | 108.73% |
| 2001 FY | -468.93 Thousand USD | -3221.63% |
| 2001 Q4 | -72.78 Thousand USD | 73.78% |
| 2001 Q3 | -277.62 Thousand USD | -73.83% |
| 2001 Q2 | -159.71 Thousand USD | -487.78% |
| 2001 Q1 | 41.18 Thousand USD | 148.47% |
| 2000 Q4 | -84.97 Thousand USD | 0.0% |
| 2000 Q2 | 20 Thousand USD | 0.0% |
| 2000 FY | 15.02 Thousand USD | -24.89% |
| 2000 Q1 | 20 Thousand USD | -50.0% |
| 2000 Q3 | - USD | -100.0% |
| 1999 Q2 | -90 Thousand USD | -550.0% |
| 1999 Q4 | 40 Thousand USD | -20.0% |
| 1999 Q3 | 50 Thousand USD | 155.56% |
| 1999 Q1 | 20 Thousand USD | 0.0% |
| 1999 FY | 20 Thousand USD | -71.43% |
| 1998 Q3 | 30 Thousand USD | 250.0% |
| 1998 Q4 | 20 Thousand USD | -33.33% |
| 1998 FY | 70 Thousand USD | 0.0% |
| 1998 Q2 | -20 Thousand USD | -150.0% |
| 1998 Q1 | 40 Thousand USD | 100.0% |
| 1997 Q1 | 30 Thousand USD | 0.0% |
| 1997 FY | 70 Thousand USD | 40.0% |
| 1997 Q4 | 20 Thousand USD | 100.0% |
| 1997 Q3 | 10 Thousand USD | -50.0% |
| 1997 Q2 | 20 Thousand USD | -33.33% |
| 1996 FY | 50 Thousand USD | 0.0% |
| 1996 Q3 | - USD | -100.0% |
| 1996 Q4 | - USD | 0.0% |
| 1996 Q2 | 10 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AbCellera Biologics Inc. | -237.2 Million USD | 96.899% |
| Alkermes plc | 414.12 Million USD | 101.776% |
| Agenus Inc. | -159.54 Million USD | 95.39% |
| Aptorum Group Limited | -10.52 Million USD | 30.098% |
| Ardelyx, Inc. | -63.27 Million USD | 88.375% |
| Dyadic International, Inc. | -8.22 Million USD | 10.617% |
| Eton Pharmaceuticals, Inc. | -1.19 Million USD | -517.114% |
| Lantern Pharma Inc. | -17.87 Million USD | 58.853% |
| Inhibikase Therapeutics, Inc. | -20.08 Million USD | 63.384% |
| Novavax, Inc. | -566.51 Million USD | 98.702% |
| Janux Therapeutics, Inc. | -72.97 Million USD | 89.92% |
| Pyxis Oncology, Inc. | -82.19 Million USD | 91.051% |
| TransCode Therapeutics, Inc. | -19.41 Million USD | 62.119% |
| Ocuphire Pharma, Inc. | -10.56 Million USD | 30.361% |
| Outlook Therapeutics, Inc. | -53.12 Million USD | 86.154% |
| Madrigal Pharmaceuticals, Inc. | -380.49 Million USD | 98.067% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.3 Million USD | 69.737% |
| SELLAS Life Sciences Group, Inc. | -37.86 Million USD | 80.575% |
| Syros Pharmaceuticals, Inc. | -128.98 Million USD | 94.297% |
| Barinthus Biotherapeutics plc | -83.91 Million USD | 91.234% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 58.059% |
| Xeris Biopharma Holdings, Inc. | -44.01 Million USD | 83.286% |
| Clearside Biomedical, Inc. | -24.84 Million USD | 70.391% |
| C4 Therapeutics, Inc. | -139.03 Million USD | 94.709% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 97.393% |
| AlloVir, Inc. | -181.33 Million USD | 95.943% |
| Arrowhead Pharmaceuticals, Inc. | -205 Million USD | 96.412% |
| VYNE Therapeutics Inc. | -29.25 Million USD | 74.858% |
| Bicycle Therapeutics plc | -189.94 Million USD | 96.127% |
| BioXcel Therapeutics, Inc. | -171.78 Million USD | 95.718% |
| ChromaDex Corporation | -5.59 Million USD | -31.381% |
| Chimerix, Inc. | -93.06 Million USD | 92.096% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | 83.681% |
| Caribou Biosciences, Inc. | -116.05 Million USD | 93.662% |
| CRISPR Therapeutics AG | -222.53 Million USD | 96.694% |
| Precision BioSciences, Inc. | -43.73 Million USD | 83.181% |
| Fate Therapeutics, Inc. | -190.51 Million USD | 96.139% |
| Fortress Biotech, Inc. | -142.34 Million USD | 94.832% |
| Fortress Biotech, Inc. | -142.34 Million USD | 94.832% |
| HOOKIPA Pharma Inc. | -97.69 Million USD | 92.47% |
| ImmuCell Corporation | -5.74 Million USD | -27.973% |
| IDEAYA Biosciences, Inc. | -134.42 Million USD | 94.528% |
| Immix Biopharma, Inc. | -16.14 Million USD | 54.427% |
| Incyte Corporation | 620.52 Million USD | 101.185% |
| Innoviva, Inc. | 176.7 Million USD | 104.163% |
| IO Biotech, Inc. | -91.44 Million USD | 91.956% |
| Jaguar Health, Inc. | -34.29 Million USD | 78.548% |
| Keros Therapeutics, Inc. | -169.94 Million USD | 95.671% |
| Ligand Pharmaceuticals Incorporated | 11.94 Million USD | 161.598% |
| ContextLogic Inc. | -328 Million USD | 97.757% |
| MiMedx Group, Inc. | 37.11 Million USD | 119.819% |
| MEI Pharma, Inc. | 14.54 Million USD | 150.585% |
| NextCure, Inc. | -67.63 Million USD | 89.124% |
| Onconetix, Inc. | -36.03 Million USD | 79.586% |
| Oncternal Therapeutics, Inc. | -41.71 Million USD | 82.366% |
| Opthea Limited | -191.84 Million USD | 96.166% |
| Psyence Biomedical Ltd. | -2.75 Million USD | -167.314% |
| Vaxcyte, Inc. | -468.04 Million USD | 98.428% |
| PDS Biotechnology Corporation | -43.04 Million USD | 82.911% |
| Precigen, Inc. | -88.92 Million USD | 91.728% |
| Pharming Group N.V. | -4.87 Million USD | -50.752% |
| Phathom Pharmaceuticals, Inc. | -167.31 Million USD | 95.603% |
| Pieris Pharmaceuticals, Inc. | -29.75 Million USD | 75.279% |
| PureTech Health plc | -146.19 Million USD | 94.969% |
| Rigel Pharmaceuticals, Inc. | -20.49 Million USD | 64.101% |
| Avidity Biosciences, Inc. | -235.59 Million USD | 96.878% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.3 Million USD | 69.737% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 97.315% |
| Sol-Gel Technologies Ltd. | -29.3 Million USD | 74.898% |
| Acelyrin, Inc. | -422.06 Million USD | 98.257% |
| Salarius Pharmaceuticals, Inc. | -12.89 Thousand USD | -56945.632% |
| Summit Therapeutics Inc. | -89.73 Million USD | 91.803% |
| Sensei Biotherapeutics, Inc. | -37.06 Million USD | 80.153% |
| Senti Biosciences, Inc. | -92.72 Million USD | 92.067% |
| Stoke Therapeutics, Inc. | -114.77 Million USD | 93.591% |
| Elevation Oncology, Inc. | -45.44 Million USD | 83.813% |
| Alaunos Therapeutics, Inc. | -34.26 Million USD | 78.533% |
| Telomir Pharmaceuticals, Inc. Common Stock | -3.94 Million USD | -86.604% |
| Entrada Therapeutics, Inc. | -3.16 Million USD | -132.638% |
| VistaGen Therapeutics, Inc. | -33.02 Million USD | 77.723% |
| Kintara Therapeutics, Inc. | -8.5 Million USD | 13.469% |
| Wave Life Sciences Ltd. | -67.99 Million USD | 89.182% |
| Seer, Inc. | -103.46 Million USD | 92.89% |
| Verrica Pharmaceuticals Inc. | -65.75 Million USD | 88.814% |
| Aadi Bioscience, Inc. | -71.93 Million USD | 89.774% |
| ESSA Pharma Inc. | -32.13 Million USD | 77.108% |
| GlycoMimetics, Inc. | -39.27 Million USD | 81.271% |
| GT Biopharma, Inc. | -13.57 Million USD | 45.816% |
| Inhibrx Biosciences, Inc. | -219.22 Million USD | 96.644% |
| Akebia Therapeutics, Inc. | -46.25 Million USD | 84.097% |
| Catalyst Pharmaceuticals, Inc. | 86.81 Million USD | 108.473% |
| Longboard Pharmaceuticals, Inc. | -56.75 Million USD | 87.04% |
| Orchestra BioMed Holdings, Inc. | -51.5 Million USD | 85.718% |
| Alzamend Neuro, Inc. | -9.93 Million USD | 25.978% |
| Sorrento Therapeutics, Inc. | -504.31 Million USD | 98.541% |
| TRACON Pharmaceuticals, Inc. | -6.89 Million USD | -6.64% |
| Viracta Therapeutics, Inc. | -50.69 Million USD | 85.489% |
| Rocket Pharmaceuticals, Inc. | -259.65 Million USD | 97.167% |
| Aptose Biosciences Inc. | -52.35 Million USD | 85.95% |
| ZyVersa Therapeutics, Inc. | -14.42 Million USD | 48.99% |
| Soligenix, Inc. | -7.69 Million USD | 4.442% |
| Century Therapeutics, Inc. | -146.54 Million USD | 94.98% |
| Kura Oncology, Inc. | -165.8 Million USD | 95.563% |
| TScan Therapeutics, Inc. | -93.45 Million USD | 92.129% |
| Intensity Therapeutics, Inc. | -8.31 Million USD | 11.576% |
| Ocean Biomedical, Inc. | -2.48 Million USD | -196.417% |
| CytomX Therapeutics, Inc. | -6.48 Million USD | -13.448% |
| Autolus Therapeutics plc | -195.02 Million USD | 96.228% |
| Mineralys Therapeutics, Inc. | -84.65 Million USD | 91.311% |
| EyePoint Pharmaceuticals, Inc. | -73.66 Million USD | 90.014% |
| Eterna Therapeutics Inc. | -21.13 Million USD | 65.195% |
| Adaptive Biotechnologies Corporation | -227.03 Million USD | 96.76% |
| GRI Bio, Inc. | -11.38 Million USD | 35.4% |
| Xenetic Biosciences, Inc. | -4.51 Million USD | -62.898% |
| Tenaya Therapeutics, Inc. | -131.19 Million USD | 94.393% |
| IGM Biosciences, Inc. | -263.46 Million USD | 97.208% |
| INmune Bio, Inc. | -29.74 Million USD | 75.266% |
| Heron Therapeutics, Inc. | -110.61 Million USD | 93.35% |
| SAB Biotherapeutics, Inc. | -38.07 Million USD | 80.68% |
| Pasithea Therapeutics Corp. | -15.97 Million USD | 53.966% |
| Entero Therapeutics, Inc. | -15.77 Million USD | 53.357% |
| Milestone Pharmaceuticals Inc. | -61.09 Million USD | 87.96% |
| X4 Pharmaceuticals, Inc. | -107.52 Million USD | 93.159% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 97.335% |
| Coherus BioSciences, Inc. | -203.19 Million USD | 96.38% |
| Verastem, Inc. | -92.08 Million USD | 92.012% |
| Abeona Therapeutics Inc. | -47.13 Million USD | 84.394% |
| Pliant Therapeutics, Inc. | -184.14 Million USD | 96.005% |
| Tonix Pharmaceuticals Holding Corp. | -118.38 Million USD | 93.786% |
| Histogen Inc. | -10.64 Million USD | 30.884% |
| Aprea Therapeutics, Inc. | -15.47 Million USD | 52.456% |
| Surrozen, Inc. | -45.78 Million USD | 83.932% |
| Organovo Holdings, Inc. | -15.08 Million USD | 51.24% |
| Lixte Biotechnology Holdings, Inc. | -5.09 Million USD | -44.512% |
| Ovid Therapeutics Inc. | -59.28 Million USD | 87.591% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 85.659% |
| CASI Pharmaceuticals, Inc. | -25.28 Million USD | 70.902% |
| Cadrenal Therapeutics, Inc. Common Stock | -7.63 Million USD | 3.627% |
| Centessa Pharmaceuticals plc | -171.28 Million USD | 95.705% |
| Hepion Pharmaceuticals, Inc. | -48.44 Million USD | 84.817% |
| Arcturus Therapeutics Holdings Inc. | -78.2 Million USD | 90.594% |
| BioRestorative Therapies, Inc. | -15.22 Million USD | 51.671% |
| Apollomics, Inc. | -54.83 Million USD | 86.585% |
| Amarin Corporation plc | -67.58 Million USD | 89.116% |
| Mesoblast Limited | -58.79 Million USD | 87.489% |
| Turnstone Biologics Corp. | -59.03 Million USD | 87.539% |
| Kymera Therapeutics, Inc. | -165.53 Million USD | 95.556% |
| Synaptogenix, Inc. | -8.31 Million USD | 11.521% |
| Tiziana Life Sciences Ltd | -14.58 Million USD | 49.568% |
| Aurinia Pharmaceuticals Inc. | -91.69 Million USD | 91.977% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | -53.523% |
| Monopar Therapeutics Inc. | -8.83 Million USD | 16.705% |
| Exelixis, Inc. | 170.88 Million USD | 104.305% |
| Better Therapeutics, Inc. | -38.26 Million USD | 80.775% |
| Nurix Therapeutics, Inc. | -155.06 Million USD | 95.256% |
| Apellis Pharmaceuticals, Inc. | -517.12 Million USD | 98.578% |
| NLS Pharmaceutics AG | -11.8 Million USD | 37.698% |
| Dermata Therapeutics, Inc. | -8.04 Million USD | 8.529% |
| Aridis Pharmaceuticals, Inc. | -29.99 Million USD | 75.474% |
| Gritstone bio, Inc. | -154.63 Million USD | 95.243% |
| Jasper Therapeutics, Inc. | -68.86 Million USD | 89.318% |
| TNF Pharmaceuticals, Inc. | -17.12 Million USD | 57.04% |
| Avid Bioservices, Inc. | -18.67 Million USD | 60.617% |
| Insmed Incorporated | -709.62 Million USD | 98.963% |
| Virpax Pharmaceuticals, Inc. | -15.68 Million USD | 53.116% |
| MediWound Ltd. | -15.29 Million USD | 51.89% |
| OmniAb, Inc. | -69.41 Million USD | 89.403% |
| Alector, Inc. | -151.74 Million USD | 95.152% |
| Seres Therapeutics, Inc. | -107.98 Million USD | 93.188% |
| Checkpoint Therapeutics, Inc. | -52.14 Million USD | 85.894% |
| Zai Lab Limited | -366.57 Million USD | 97.993% |
| Revance Therapeutics, Inc. | -316.77 Million USD | 97.678% |
| Aura Biosciences, Inc. | -84.99 Million USD | 91.345% |
| Lyell Immunopharma, Inc. | -245.49 Million USD | 97.004% |
| Immunic, Inc. | -99.22 Million USD | 92.586% |
| Tarsus Pharmaceuticals, Inc. | -143.15 Million USD | 94.862% |
| Veracyte, Inc. | -85.79 Million USD | 91.426% |
| InMed Pharmaceuticals Inc. | - USD | Infinity% |
| FibroGen, Inc. | -281.81 Million USD | 97.39% |
| SeaStar Medical Holding Corporation | -14.21 Million USD | 48.234% |
| Adial Pharmaceuticals, Inc. | -6.88 Million USD | -6.795% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.79 Million USD | 60.857% |
| Jazz Pharmaceuticals plc | 578.58 Million USD | 101.271% |
| Cyclacel Pharmaceuticals, Inc. | -25.45 Million USD | 71.1% |
| Amylyx Pharmaceuticals, Inc. | 38.8 Million USD | 118.958% |
| TG Therapeutics, Inc. | 20.63 Million USD | 135.652% |
| Galecto, Inc. | -39.9 Million USD | 81.566% |
| Calithera Biosciences, Inc. | -42.07 Million USD | 82.517% |
| Fortrea Holdings Inc. | 63.1 Million USD | 111.658% |
| KalVista Pharmaceuticals, Inc. | -140.44 Million USD | 94.762% |
| Aptevo Therapeutics Inc. | -28.87 Million USD | 74.527% |
| XBiotech Inc. | -37.51 Million USD | 80.389% |
| Jasper Therapeutics, Inc. | -68.86 Million USD | 89.318% |
| Lyra Therapeutics, Inc. | -67.12 Million USD | 89.041% |
| Foghorn Therapeutics Inc. | -107.9 Million USD | 93.183% |
| Y-mAbs Therapeutics, Inc. | -25.67 Million USD | 71.346% |
| Theravance Biopharma, Inc. | -53.29 Million USD | 86.197% |
| Ultragenyx Pharmaceutical Inc. | -569.2 Million USD | 98.708% |
| Metagenomi, Inc. Common Stock | -78.49 Million USD | 90.628% |
| Vaxxinity, Inc. | -58.28 Million USD | 87.379% |
| BioCryst Pharmaceuticals, Inc. | -103.7 Million USD | 92.907% |
| Gain Therapeutics, Inc. | -22.25 Million USD | 66.944% |
| Cartesian Therapeutics, Inc. | -86.41 Million USD | 91.488% |
| NexImmune, Inc. | -29.19 Million USD | 74.802% |
| Creative Medical Technology Holdings, Inc. | -5.62 Million USD | -30.887% |
| Marker Therapeutics, Inc. | -14.58 Million USD | 49.552% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 100.182% |
| Chemomab Therapeutics Ltd. | -25.45 Million USD | 71.106% |
| Scopus BioPharma Inc. | -11.71 Million USD | 37.208% |
| RAPT Therapeutics, Inc. | -127.06 Million USD | 94.211% |
| Ainos, Inc. | -13.2 Million USD | 44.3% |
| Pluri Inc. | -22.15 Million USD | 66.802% |
| Prothena Corporation plc | -191.03 Million USD | 96.149% |
| Adaptimmune Therapeutics plc | -138.03 Million USD | 94.671% |
| Celularity Inc. | -192.28 Million USD | 96.174% |
| Rallybio Corporation | -78.93 Million USD | 90.681% |
| Cue Biopharma, Inc. | -52.14 Million USD | 85.894% |
| MeiraGTx Holdings plc | -137.06 Million USD | 94.633% |
| Omeros Corporation | -164.53 Million USD | 95.529% |
| Humacyte, Inc. | -100.04 Million USD | 92.647% |
| Immunocore Holdings plc | -59.64 Million USD | 87.668% |
| Cocrystal Pharma, Inc. | -18.55 Million USD | 60.364% |
| Cidara Therapeutics, Inc. | -24.48 Million USD | 69.955% |
| Blueprint Medicines Corporation | -486.27 Million USD | 98.487% |
| CalciMedica, Inc. | -21.87 Million USD | 66.373% |
| Cabaletta Bio, Inc. | -74.66 Million USD | 90.147% |
| Marinus Pharmaceuticals, Inc. | -131.48 Million USD | 94.405% |
| Scholar Rock Holding Corporation | -171.29 Million USD | 95.706% |
| Sana Biotechnology, Inc. | -326.9 Million USD | 97.75% |
| Pulmatrix, Inc. | -14.74 Million USD | 50.095% |
| Elicio Therapeutics, Inc. | -35.74 Million USD | 79.421% |
| Vigil Neuroscience, Inc. | -88.86 Million USD | 91.722% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 98.572% |
| Adlai Nortye Ltd. American Depositary Shares | -67.55 Million USD | 89.11% |
| Cytokinetics, Incorporated | -496.2 Million USD | 98.518% |
| Eloxx Pharmaceuticals, Inc. | -34.41 Million USD | 78.628% |
| Nutriband Inc. | -4.87 Million USD | -50.988% |
| Protara Therapeutics, Inc. | -43.61 Million USD | 83.133% |
| Vor Biopharma Inc. | -126.03 Million USD | 94.164% |
| Roivant Sciences Ltd. | 4.24 Billion USD | 100.173% |
| Evogene Ltd. | -26.39 Million USD | 72.127% |
| ProKidney Corp. | -151.52 Million USD | 95.145% |
| Applied Therapeutics, Inc. | -64.53 Million USD | 88.602% |
| Hoth Therapeutics, Inc. | -7.69 Million USD | 4.371% |
| BridgeBio Pharma, Inc. | -607.37 Million USD | 98.789% |
| CorMedix Inc. | -48.95 Million USD | 84.975% |
| BioLineRx Ltd. | -49.69 Million USD | 85.197% |
| Tango Therapeutics, Inc. | -114.17 Million USD | 93.557% |
| Galectin Therapeutics Inc. | -38.07 Million USD | 80.679% |
| Atai Life Sciences N.V. | -125.47 Million USD | 94.137% |
| Renovaro Biosciences Inc. | -81.63 Million USD | 90.99% |
| Aerovate Therapeutics, Inc. | -81.4 Million USD | 90.964% |
| Zentalis Pharmaceuticals, Inc. | -248.98 Million USD | 97.046% |
| Sagimet Biosciences Inc. | -30.74 Million USD | 76.07% |
| MediciNova, Inc. | -9.9 Million USD | 25.699% |
| Praxis Precision Medicines, Inc. | -126.37 Million USD | 94.179% |
| Cardio Diagnostics Holdings, Inc. | -7.24 Million USD | -1.568% |
| GeoVax Labs, Inc. | -26.74 Million USD | 72.494% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 96.827% |
| Biomea Fusion, Inc. | -126.13 Million USD | 94.168% |
| PTC Therapeutics, Inc. | -349.4 Million USD | 97.895% |
| Mereo BioPharma Group plc | -28.41 Million USD | 74.113% |
| Cullinan Oncology, Inc. | -191.08 Million USD | 96.15% |
| Syndax Pharmaceuticals, Inc. | -229.95 Million USD | 96.801% |
| Absci Corporation | -115.51 Million USD | 93.632% |
| NRx Pharmaceuticals, Inc. | -27.58 Million USD | 73.335% |
| 4D Molecular Therapeutics, Inc. | -112.86 Million USD | 93.483% |
| Dyne Therapeutics, Inc. | -242.16 Million USD | 96.962% |
| Kiniksa Pharmaceuticals, Ltd. | -25.19 Million USD | 70.805% |
| Ventyx Biosciences, Inc. | -207.99 Million USD | 96.463% |
| Allakos Inc. | -196.05 Million USD | 96.248% |
| Imunon, Inc. | -21.03 Million USD | 65.022% |
| Fulcrum Therapeutics, Inc. | -110.66 Million USD | 93.353% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | 106.857% |
| BioAtla, Inc. | -129.68 Million USD | 94.328% |
| NLS Pharmaceutics AG | -11.8 Million USD | 37.698% |
| Bio-Path Holdings, Inc. | -15.84 Million USD | 53.569% |
| Allogene Therapeutics, Inc. | -327.73 Million USD | 97.756% |
| Larimar Therapeutics, Inc. | -41.75 Million USD | 82.384% |
| XOMA Corporation | -41.84 Million USD | 82.422% |
| Kezar Life Sciences, Inc. | -105.23 Million USD | 93.01% |
| Cara Therapeutics, Inc. | -121.49 Million USD | 93.945% |
| aTyr Pharma, Inc. | -54.91 Million USD | 86.606% |
| Aligos Therapeutics, Inc. | -87.42 Million USD | 91.586% |
| Akero Therapeutics, Inc. | -172.87 Million USD | 95.745% |
| Viridian Therapeutics, Inc. | -254.45 Million USD | 97.109% |
| Eliem Therapeutics, Inc. | -21.46 Million USD | 65.732% |
| EyeGate Pharmaceuticals, Inc. | -8.21 Million USD | 10.432% |
| Akari Therapeutics, Plc | -16.8 Million USD | 56.23% |
| Tevogen Bio Holdings Inc. | -8843.03 USD | -83084.157% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 102.179% |
| Lexaria Bioscience Corp. | -6.53 Million USD | -12.58% |
| UroGen Pharma Ltd. | -65.53 Million USD | 88.776% |
| Sutro Biopharma, Inc. | -89.27 Million USD | 91.761% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | -1.28% |
| Orgenesis Inc. | -53.63 Million USD | 86.285% |
| Entera Bio Ltd. | -8.89 Million USD | 17.265% |
| GH Research PLC | -41.22 Million USD | 82.155% |
| Lisata Therapeutics, Inc. | -25.7 Million USD | 71.386% |
| Reneo Pharmaceuticals, Inc. | -83.05 Million USD | 91.143% |
| Xencor, Inc. | -138.63 Million USD | 94.694% |
| 60 Degrees Pharmaceuticals, Inc. | -5.15 Million USD | -42.708% |
| Replimune Group, Inc. | -234.77 Million USD | 96.867% |
| Coeptis Therapeutics Holdings, Inc. | -21.49 Million USD | 65.772% |
| Vanda Pharmaceuticals Inc. | -13.95 Million USD | 47.276% |
| Lexaria Bioscience Corp. | -6.53 Million USD | -12.58% |
| Portage Biotech Inc. | -18.25 Million USD | 59.7% |
| Cardio Diagnostics Holdings, Inc. | -7.24 Million USD | -1.568% |
| Olema Pharmaceuticals, Inc. | -104.96 Million USD | 92.992% |
| OncoCyte Corporation | -25.13 Million USD | 70.735% |
| Qualigen Therapeutics, Inc. | -11.3 Million USD | 34.931% |
| Processa Pharmaceuticals, Inc. | -11.45 Million USD | 35.795% |
| Purple Biotech Ltd. | 22.27 Million USD | 133.03% |
| CollPlant Biotechnologies Ltd. | -7.51 Million USD | 2.077% |
| scPharmaceuticals Inc. | -55.39 Million USD | 86.721% |
| ProMIS Neurosciences, Inc. | -18.89 Million USD | 61.075% |
| HilleVax, Inc. | -133.34 Million USD | 94.483% |
| NeuroSense Therapeutics Ltd. | -12.04 Million USD | 38.949% |
| Tharimmune, Inc. | -9.45 Million USD | 22.202% |
| Genprex, Inc. | -31.07 Million USD | 76.329% |
| Neumora Therapeutics, Inc. Common Stock | -188.19 Million USD | 96.091% |
| Atossa Therapeutics, Inc. | -31.37 Million USD | 76.556% |
| XTL Biopharmaceuticals Ltd. | -765 Thousand USD | -861.569% |
| Virios Therapeutics, Inc. | -5.44 Million USD | -35.049% |
| OKYO Pharma Limited | -15.74 Thousand USD | -46605.563% |
| Savara Inc. | -60 Million USD | 87.741% |
| Curis, Inc. | -48.33 Million USD | 84.78% |
| Daré Bioscience, Inc. | -30.83 Million USD | 76.148% |
| Carmell Therapeutics Corporation | -5.21 Million USD | -40.993% |
| Titan Pharmaceuticals, Inc. | -7.27 Million USD | -1.086% |
| Achieve Life Sciences, Inc. | -27.25 Million USD | 73.006% |
| BeiGene, Ltd. | -1.2 Billion USD | 99.391% |
| Kiromic BioPharma, Inc. | -19.93 Million USD | 63.108% |
| Revolution Medicines, Inc. Warrant | -487.18 Million USD | 98.49% |
| Protagonist Therapeutics, Inc. | -93.65 Million USD | 92.145% |
| Erasca, Inc. | -141.52 Million USD | 94.802% |
| bluebird bio, Inc. | -244.26 Million USD | 96.988% |
| Protagenic Therapeutics, Inc. | -4.52 Million USD | -62.493% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | 103.783% |
| DBV Technologies S.A. | -76.43 Million USD | 90.376% |
| Protagenic Therapeutics, Inc. | -4.52 Million USD | -62.493% |
| Moderna, Inc. | -4.23 Billion USD | 99.826% |
| Vincerx Pharma, Inc. | -42.6 Million USD | 82.736% |
| Fresh Tracks Therapeutics, Inc. | -6.36 Million USD | -15.66% |
| Molecular Templates, Inc. | -10.46 Million USD | 29.715% |
| Acrivon Therapeutics, Inc. Common Stock | -67.23 Million USD | 89.06% |
| Travere Therapeutics, Inc. | -376.74 Million USD | 98.047% |
| Monte Rosa Therapeutics, Inc. | -143.31 Million USD | 94.867% |
| Spruce Biosciences, Inc. | -51.99 Million USD | 85.852% |
| Celldex Therapeutics, Inc. | -154.54 Million USD | 95.24% |
| Cogent Biosciences, Inc. | -208.13 Million USD | 96.466% |
| MacroGenics, Inc. | -168.24 Million USD | 95.628% |
| RenovoRx, Inc. | -11.39 Million USD | 35.451% |
| Adicet Bio, Inc. | -152.03 Million USD | 95.162% |
| Prime Medicine, Inc. | -191.29 Million USD | 96.155% |
| Aditxt, Inc. | -26.06 Million USD | 71.775% |
| Adagene Inc. | -23.71 Million USD | 68.988% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -0.628% |
| Quantum-Si incorporated | -111.17 Million USD | 93.383% |
| Maravai LifeSciences Holdings, Inc. | -31.64 Million USD | 76.757% |
| Acurx Pharmaceuticals, Inc. | -14.57 Million USD | 49.54% |
| Voyager Therapeutics, Inc. | 122.01 Million USD | 106.029% |
| SciSparc Ltd. | -5.77 Million USD | -27.421% |
| Vericel Corporation | -6.46 Million USD | -13.8% |
| Revelation Biosciences, Inc. | -8.65 Million USD | 15.025% |
| Minerva Neurosciences, Inc. | -23.11 Million USD | 68.183% |
| Generation Bio Co. | -138.56 Million USD | 94.691% |
| Astria Therapeutics, Inc. | -83.03 Million USD | 91.141% |
| Black Diamond Therapeutics, Inc. | -86.46 Million USD | 91.492% |
| Arcutis Biotherapeutics, Inc. | -241.1 Million USD | 96.949% |
| Invivyd, Inc. | -207.78 Million USD | 96.46% |
| Relay Therapeutics, Inc. | -373 Million USD | 98.028% |
| Quoin Pharmaceuticals, Ltd. | -9.37 Million USD | 21.565% |
| Spero Therapeutics, Inc. | 21.48 Million USD | 134.244% |
| Artelo Biosciences, Inc. | -10.28 Million USD | 28.492% |
| 2seventy bio, Inc. | -216.7 Million USD | 96.605% |
| ADMA Biologics, Inc. | 21.63 Million USD | 134.005% |
| Clene Inc. | -40.54 Million USD | 81.855% |
| Capricor Therapeutics, Inc. | -24.07 Million USD | 69.449% |
| Boundless Bio, Inc. Common Stock | -54.79 Million USD | 86.576% |
| GeoVax Labs, Inc. | -26.74 Million USD | 72.494% |
| Recursion Pharmaceuticals, Inc. | -350.06 Million USD | 97.899% |
| Citius Pharmaceuticals, Inc. | -36.73 Million USD | 79.974% |
| Contineum Therapeutics, Inc. Class A Common Stock | 16.07 Million USD | 145.755% |
| Relmada Therapeutics, Inc. | -103.7 Million USD | 92.907% |
| Finch Therapeutics Group, Inc. | -34 Million USD | 78.366% |
| ALX Oncology Holdings Inc. | -170.27 Million USD | 95.68% |
| Vir Biotechnology, Inc. | -684.3 Million USD | 98.925% |
| Evaxion Biotech A/S | -22.19 Million USD | 66.86% |
| Ocular Therapeutix, Inc. | -82.38 Million USD | 91.071% |
| Verve Therapeutics, Inc. | -223.12 Million USD | 96.703% |
| Trevena, Inc. | -35.28 Million USD | 79.154% |
| Surrozen, Inc. | -45.78 Million USD | 83.932% |
| Tyra Biosciences, Inc. | -79.94 Million USD | 90.799% |
| Cingulate Inc. | -22.75 Million USD | 67.679% |
| Galmed Pharmaceuticals Ltd. | 7.49 Million USD | 198.185% |
| Unity Biotechnology, Inc. | -44.66 Million USD | 83.531% |
| Tenax Therapeutics, Inc. | -8.23 Million USD | 10.662% |
| Terns Pharmaceuticals, Inc. | -102.55 Million USD | 92.827% |
| ACADIA Pharmaceuticals Inc. | -73.37 Million USD | 89.975% |
| Connect Biopharma Holdings Limited | -62.07 Million USD | 88.15% |
| Clearmind Medicine Inc. | -8.74 Million USD | 15.848% |
| Kronos Bio, Inc. | -121.83 Million USD | 93.962% |
| Bolt Biotherapeutics, Inc. | -76.19 Million USD | 90.346% |
| CERo Therapeutics Holdings, Inc. | -2.93 Million USD | -150.803% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 92.704% |
| Statera Biopharma, Inc. | -98.34 Million USD | 92.52% |
| ImmunityBio, Inc. | -362.25 Million USD | 97.969% |
| Korro Bio, Inc. | -84.53 Million USD | 91.298% |
| Kineta, Inc. | -15.72 Million USD | 53.215% |
| BioVie Inc. | -32.17 Million USD | 77.141% |
| Codexis, Inc. | -68.06 Million USD | 89.193% |
| Celularity Inc. | -192.28 Million USD | 96.174% |
| Crinetics Pharmaceuticals, Inc. | -222.6 Million USD | 96.696% |
| Celcuity Inc. | -66.23 Million USD | 88.893% |
| Virax Biolabs Group Limited | -6.49 Million USD | -13.231% |
| Cibus, Inc. | -318.88 Million USD | 97.693% |
| Eledon Pharmaceuticals, Inc. | -43 Million USD | 82.893% |
| eFFECTOR Therapeutics, Inc. | -33.84 Million USD | 78.265% |
| IN8bio, Inc. | -30.33 Million USD | 75.752% |
| Kodiak Sciences Inc. | -277.32 Million USD | 97.347% |
| Annexon, Inc. | -143.72 Million USD | 94.882% |
| Adverum Biotechnologies, Inc. | -123.79 Million USD | 94.058% |
| Assembly Biosciences, Inc. | -64.64 Million USD | 88.621% |
| Avalo Therapeutics, Inc. | -23.44 Million USD | 68.623% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 97.92% |
| Eyenovia, Inc. | -25.4 Million USD | 71.047% |
| Puma Biotechnology, Inc. | 32.64 Million USD | 122.537% |
| Conduit Pharmaceuticals Inc. | -5.56 Million USD | -32.255% |
| Xilio Therapeutics, Inc. | -79.13 Million USD | 90.704% |
| Arcellx, Inc. | -89.88 Million USD | 91.816% |
| Cardiff Oncology, Inc. | -45.41 Million USD | 83.802% |
| Enanta Pharmaceuticals, Inc. | -137.2 Million USD | 94.639% |
| Regulus Therapeutics Inc. | -31.1 Million USD | 76.354% |
| Moolec Science SA | -6.65 Million USD | -10.553% |
| Acumen Pharmaceuticals, Inc. | -61.13 Million USD | 87.968% |
| Geron Corporation | -193.94 Million USD | 96.207% |
| LAVA Therapeutics N.V. | -43.25 Million USD | 82.993% |
| Royalty Pharma plc | 1.49 Billion USD | 100.493% |
| Atea Pharmaceuticals, Inc. | -164.16 Million USD | 95.519% |
| Greenwich LifeSciences, Inc. | -9.32 Million USD | 21.14% |
| TFF Pharmaceuticals, Inc. | -21.89 Million USD | 66.403% |
| Mersana Therapeutics, Inc. | -170.95 Million USD | 95.697% |
| Humacyte, Inc. | -100.04 Million USD | 92.647% |
| Structure Therapeutics Inc. | -102.77 Million USD | 92.843% |
| 89bio, Inc. | -151.2 Million USD | 95.135% |
| PMV Pharmaceuticals, Inc. | -80.13 Million USD | 90.82% |
| Avenue Therapeutics, Inc. | -14.54 Million USD | 49.409% |
| Genelux Corporation | -24.16 Million USD | 69.559% |
| Trevi Therapeutics, Inc. | -33.92 Million USD | 78.316% |
| Lexicon Pharmaceuticals, Inc. | -171.75 Million USD | 95.717% |
| Notable Labs, Ltd. | -14.65 Million USD | 49.812% |
| Liquidia Corporation | -73.38 Million USD | 89.976% |
| Mustang Bio, Inc. | -50.72 Million USD | 85.499% |
| Immunovant, Inc. | -282.7 Million USD | 97.398% |
| Quantum-Si incorporated | -111.17 Million USD | 93.383% |
| Arbutus Biopharma Corporation | -78.1 Million USD | 90.582% |
| DiaMedica Therapeutics Inc. | -21.26 Million USD | 65.411% |
| Vera Therapeutics, Inc. | -102.01 Million USD | 92.789% |
| Acasti Pharma Inc. | -11.31 Million USD | 34.972% |
| MiNK Therapeutics, Inc. | -22.92 Million USD | 67.907% |
| Pasithea Therapeutics Corp. | -15.97 Million USD | 53.966% |
| Xenon Pharmaceuticals Inc. | -214.05 Million USD | 96.563% |
| Elevai Labs, Inc. Common Stock | -3.66 Million USD | -100.487% |
| NeuroBo Pharmaceuticals, Inc. | -15.88 Million USD | 53.695% |
| Tempest Therapeutics, Inc. | -29.15 Million USD | 74.771% |
| Soleno Therapeutics, Inc. | -41.38 Million USD | 82.225% |
| PepGen Inc. | -84.76 Million USD | 91.322% |
| Moleculin Biotech, Inc. | -29.63 Million USD | 75.175% |
| United Therapeutics Corporation | 1.18 Billion USD | 100.621% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | 67.874% |
| Solid Biosciences Inc. | -104.31 Million USD | 92.948% |
| BriaCell Therapeutics Corp. | -32.8 Million USD | 77.579% |
| Immuneering Corporation | -58.41 Million USD | 87.407% |
| Lixte Biotechnology Holdings, Inc. | -5.09 Million USD | -44.512% |
| Silo Pharma, Inc. | -3.85 Million USD | -90.788% |
| Belite Bio, Inc | -31.66 Million USD | 76.772% |
| XOMA Corporation | -41.84 Million USD | 82.422% |
| ARS Pharmaceuticals, Inc. | -67.52 Million USD | 89.105% |
| Bionomics Limited | -17.89 Billion USD | 99.959% |
| Apogee Therapeutics, Inc. | -93 Million USD | 92.091% |
| Alpha Tau Medical Ltd. | 35.68 Million USD | 120.617% |
| uniQure N.V. | -282.87 Million USD | 97.4% |
| Cassava Sciences, Inc. | -105.95 Million USD | 93.058% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -0.628% |
| Poseida Therapeutics, Inc. | -129.5 Million USD | 94.32% |
| Forte Biosciences, Inc. | -32.48 Million USD | 77.356% |
| Anebulo Pharmaceuticals, Inc. | -8.3 Million USD | 11.467% |
| Enlivex Therapeutics Ltd. | -29.39 Million USD | 74.975% |
| Conduit Pharmaceuticals Inc. | -5.56 Million USD | -32.255% |
| SeaStar Medical Holding Corporation | -14.21 Million USD | 48.234% |
| FibroBiologics, Inc. Common Stock | -8.88 Million USD | 17.246% |
| Altimmune, Inc. | -95.92 Million USD | 92.332% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | 89.991% |
| Alpha Tau Medical Ltd. | 35.68 Million USD | 120.617% |
| Compugen Ltd. | -12.99 Million USD | 43.381% |
| Peak Bio, Inc. | -1356.23 USD | -542285.879% |
| Zevra Therapeutics, Inc. | -49.6 Million USD | 85.171% |
| Benitec Biopharma Inc. | -22.49 Million USD | 67.292% |
| Spyre Therapeutics, Inc. | -242.3 Million USD | 96.964% |
| NKGen Biotech, Inc. Common Stock | -29.74 Million USD | 75.271% |
| Zura Bio Limited | -62.63 Million USD | 88.256% |
| PolyPid Ltd. | -22.86 Million USD | 67.831% |
| Aileron Therapeutics, Inc. | -16.27 Million USD | 54.805% |
| NKGen Biotech, Inc. Warrants | -29.74 Million USD | 75.271% |
| Instil Bio, Inc. | -159.16 Million USD | 95.378% |
| argenx SE | -425.04 Million USD | 98.269% |
| Immunome, Inc. | -109.53 Million USD | 93.284% |
| Compass Therapeutics, Inc. | -50.36 Million USD | 85.394% |
| Verona Pharma plc | -67.83 Million USD | 89.155% |
| enGene Holdings Inc. Warrants | -26.06 Million USD | 71.773% |
| Shattuck Labs, Inc. | -91.95 Million USD | 92.001% |
| CervoMed Inc. | -7.81 Million USD | 5.848% |
| LENZ Therapeutics, Inc. | -73.11 Million USD | 89.938% |
| Plus Therapeutics, Inc. | -13.32 Million USD | 44.779% |
| Dianthus Therapeutics, Inc. | -48.17 Million USD | 84.73% |
| Moolec Science SA | -6.65 Million USD | -10.553% |
| Enveric Biosciences, Inc. | -16.44 Million USD | 55.278% |
| Inovio Pharmaceuticals, Inc. | -135.22 Million USD | 94.56% |
| AnaptysBio, Inc. | -164.41 Million USD | 95.526% |
| Design Therapeutics, Inc. | -78.19 Million USD | 90.592% |
| Leap Therapeutics, Inc. | -87.04 Million USD | 91.549% |
| NeurAxis, Inc. | -6.66 Million USD | -10.376% |
| Seelos Therapeutics, Inc. | -40.49 Million USD | 81.837% |
| Lumos Pharma, Inc. | -36.61 Million USD | 79.909% |
| Achilles Therapeutics plc | -75.25 Million USD | 90.225% |
| enGene Holdings Inc. Common Stock | -26.06 Million USD | 71.773% |
| 180 Life Sciences Corp. | -13.47 Million USD | 45.42% |
| Opiant Pharmaceuticals, Inc. | 5.15 Million USD | 242.66% |
| CERo Therapeutics Holdings, Inc. | -2.93 Million USD | -150.803% |
| Nutriband Inc. | -4.87 Million USD | -50.988% |
| ORIC Pharmaceuticals, Inc. | -110.78 Million USD | 93.36% |
| CG Oncology, Inc. Common stock | -55.44 Million USD | 86.734% |
| Fractyl Health, Inc. Common Stock | -50.83 Million USD | 85.53% |
| Rani Therapeutics Holdings, Inc. | -66.09 Million USD | 88.871% |
| MoonLake Immunotherapeutics | -54.12 Million USD | 86.409% |
| Palisade Bio, Inc. | -13.07 Million USD | 43.718% |
| Tourmaline Bio, Inc. | -45.4 Million USD | 83.801% |
| Beam Therapeutics Inc. | -176.48 Million USD | 95.832% |
| Neurogene Inc. | -55.58 Million USD | 86.766% |
| Mirum Pharmaceuticals, Inc. | -109.15 Million USD | 93.261% |
| AEON Biopharma, Inc. | -48.42 Million USD | 84.811% |
| CARGO Therapeutics, Inc. Common Stock | -96.71 Million USD | 92.394% |
| Sesen Bio, Inc. | -25.9 Million USD | 71.608% |
| Enliven Therapeutics, Inc. | -83.52 Million USD | 91.193% |
| Kiora Pharmaceuticals, Inc. | -12.58 Million USD | 41.558% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 98.403% |
| Taysha Gene Therapies, Inc. | -72.43 Million USD | 89.845% |
| Athira Pharma, Inc. | -125.46 Million USD | 94.137% |
| Vaccinex, Inc. | -22.88 Million USD | 67.857% |
| HCW Biologics Inc. | -25.71 Million USD | 71.397% |
| XOMA Corporation | -41.84 Million USD | 82.422% |
| Nektar Therapeutics | -137.42 Million USD | 94.647% |
| Arvinas, Inc. | -401.5 Million USD | 98.168% |
| Tevogen Bio Holdings Inc. | -8843.03 USD | -83084.157% |
| Merus N.V. | -156.54 Million USD | 95.301% |
| Omega Therapeutics, Inc. | -100.26 Million USD | 92.663% |
| Quince Therapeutics, Inc. | -34.62 Million USD | 78.752% |
| Rezolute, Inc. | -70.42 Million USD | 89.555% |
| Clene Inc. | -40.54 Million USD | 81.855% |
| Indaptus Therapeutics, Inc. | -16.37 Million USD | 55.087% |
| BeyondSpring Inc. | -23.11 Million USD | 68.175% |
| Synlogic, Inc. | -55.16 Million USD | 86.664% |
| Allarity Therapeutics, Inc. | -17.92 Million USD | 58.971% |
| Phio Pharmaceuticals Corp. | -10.82 Million USD | 32.04% |
| Peak Bio, Inc. | -1356.23 USD | -542285.879% |
| Werewolf Therapeutics, Inc. | -40.5 Million USD | 81.838% |
| Krystal Biotech, Inc. | -109.72 Million USD | 93.296% |
| Karyopharm Therapeutics Inc. | -129.53 Million USD | 94.321% |
| SpringWorks Therapeutics, Inc. | -343.01 Million USD | 97.855% |
| Lipella Pharmaceuticals Inc. | -4.74 Million USD | -54.995% |
| MannKind Corporation | 8.67 Million USD | 184.766% |
| Ikena Oncology, Inc. | -75.41 Million USD | 90.246% |
| Cyclerion Therapeutics, Inc. | -9.64 Million USD | 23.748% |
| Gyre Therapeutics, Inc. | -67.23 Million USD | 89.058% |
| Gossamer Bio, Inc. | -183.75 Million USD | 95.997% |
| CohBar, Inc. | -12.38 Million USD | 40.621% |
| Cognition Therapeutics, Inc. | -50.72 Million USD | 85.498% |
| NRx Pharmaceuticals, Inc. | -27.58 Million USD | 73.335% |
| Legend Biotech Corporation | -439.48 Million USD | 98.326% |
| Mural Oncology plc | -194.63 Million USD | 96.221% |
| Biora Therapeutics, Inc. | -67.14 Million USD | 89.044% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | 54.439% |
| Disc Medicine, Inc. | -91.12 Million USD | 91.928% |
| REGENXBIO Inc. | -268.12 Million USD | 97.257% |
| Ensysce Biosciences, Inc. | -10.71 Million USD | 31.369% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 86.807% |
| Cellectar Biosciences, Inc. | -38.96 Million USD | 81.119% |
| Edgewise Therapeutics, Inc. | -114.35 Million USD | 93.568% |
| Vaxart, Inc. | -83.34 Million USD | 91.174% |
| PharmaCyte Biotech, Inc. | -8.52 Million USD | 13.662% |
| Aldeyra Therapeutics, Inc. | -42.79 Million USD | 82.811% |
| Cellectis S.A. | -106.62 Million USD | 93.101% |
| Longeveron Inc. | -21.02 Million USD | 65.02% |
| Repare Therapeutics Inc. | -116.22 Million USD | 93.671% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 97.253% |
| Inozyme Pharma, Inc. | -75.64 Million USD | 90.276% |
| Revolution Medicines, Inc. | -487.18 Million USD | 98.49% |
| Nymox Pharmaceutical Corporation | -6.65 Million USD | -10.583% |
| Third Harmonic Bio, Inc. | -43.95 Million USD | 83.264% |
| ArriVent BioPharma, Inc. Common Stock | -74.59 Million USD | 90.138% |
| AN2 Therapeutics, Inc. | -69.63 Million USD | 89.436% |
| Anixa Biosciences, Inc. | -11.01 Million USD | 33.194% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 100.171% |
| Denali Therapeutics Inc. | -196.69 Million USD | 96.26% |
| Revelation Biosciences, Inc. | -8.65 Million USD | 15.025% |
| Veru Inc. | -93.78 Million USD | 92.156% |
| Corvus Pharmaceuticals, Inc. | -23.32 Million USD | 68.468% |
| Cingulate Inc. | -22.75 Million USD | 67.679% |
| Passage Bio, Inc. | -108.38 Million USD | 93.213% |
| Context Therapeutics Inc. | -25.07 Million USD | 70.661% |
| Exicure, Inc. | -14.99 Million USD | 50.947% |
| Day One Biopharmaceuticals, Inc. | -206.06 Million USD | 96.43% |
| Oramed Pharmaceuticals Inc. | -40.59 Million USD | 81.881% |
| Scinai Immunotherapeutics Ltd. | -9.71 Million USD | 24.297% |
| Rhythm Pharmaceuticals, Inc. | -184.35 Million USD | 96.01% |
| Nuvalent, Inc. | -149.49 Million USD | 95.079% |
| ABVC BioPharma, Inc. | -8.21 Million USD | 10.473% |
| Carisma Therapeutics, Inc. | -88.73 Million USD | 91.71% |
| Unicycive Therapeutics, Inc. | -20.77 Million USD | 64.59% |
| OmniAb, Inc. | -69.41 Million USD | 89.403% |
| Anew Medical, Inc. | -1.3 Million USD | -465.481% |
| Fennec Pharmaceuticals Inc. | -12.77 Million USD | 42.401% |
| Lipocine Inc. | -17.93 Million USD | 58.976% |
| Lexeo Therapeutics, Inc. Common Stock | -68.51 Million USD | 89.263% |
| Nautilus Biotechnology, Inc. | -76.15 Million USD | 90.34% |
| SAB Biotherapeutics, Inc. | -38.07 Million USD | 80.68% |
| G1 Therapeutics, Inc. | -39.52 Million USD | 81.39% |
| Bellerophon Therapeutics, Inc. | -22.38 Million USD | 67.137% |
| Sage Therapeutics, Inc. | -579.84 Million USD | 98.731% |
| Ocugen, Inc. | -65.53 Million USD | 88.775% |
| Mind Medicine (MindMed) Inc. | -93.86 Million USD | 92.163% |
| Q32 Bio Inc. | -92.1 Million USD | 92.013% |
| Brainstorm Cell Therapeutics Inc. | -21.43 Million USD | 65.689% |
| Alumis Inc. Common Stock | -158.17 Million USD | 95.349% |
| Equillium, Inc. | -14.52 Million USD | 49.346% |
| Kyverna Therapeutics, Inc. | -62.4 Million USD | 88.213% |
| Coya Therapeutics, Inc. | -7.9 Million USD | 6.926% |
| CNS Pharmaceuticals, Inc. | -18.86 Million USD | 61.007% |
| Galera Therapeutics, Inc. | -46.95 Million USD | 84.333% |
| Evelo Biosciences, Inc. | -108.46 Million USD | 93.218% |
| Comera Life Sciences Holdings, Inc. | -11.97 Million USD | 38.546% |
| Dominari Holdings Inc. | -21.79 Million USD | 66.251% |
| Edesa Biotech, Inc. | -9.22 Million USD | 20.241% |
| vTv Therapeutics Inc. | -25.5 Million USD | 71.155% |
| Bio-Techne Corporation | 206.68 Million USD | 103.559% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 98.121% |
| Harmony Biosciences Holdings, Inc. | 192.03 Million USD | 103.831% |
| Prelude Therapeutics Incorporated | -132.27 Million USD | 94.439% |
| Candel Therapeutics, Inc. | -38.39 Million USD | 80.839% |
| iTeos Therapeutics, Inc. | -151.1 Million USD | 95.132% |
| Nkarta, Inc. | -131.65 Million USD | 94.412% |
| BioCardia, Inc. | -11.64 Million USD | 36.826% |
| Iterum Therapeutics plc | -47.46 Million USD | 84.503% |